A Double‐Blind Randomized Placebo‐Controlled Trial of Sibutramine
Obesity ResearchPublished 1 May 1996Open access
George A. Bray, Donna H. Ryan, Douglas Gordon, Sylvia A. Heidingsfelder, Frederick P. Cerise, Krause Wilson
Citations189
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
There was a dose-dependent reduction in body weight, with doses of 10, 15, 20 and 30 mg being significantly greater than placebo and weight loss was still continuing in the highest three doses at the end of the study.
Abstract
Sibutramine is a beta-phenethylamine which blocks reuptake of norepinephrine and serotonin. In this clinical study, a group of 173 patients were randomized to treatment with sibutramine at doses of 1, 5, 10, 15, 20 or 30 mg/d and were compared with placebo in a 24-week double-blind trial. There was a dose-dependent reduction in body weight, with doses of 10, 15, 20 and 30 mg being significantly greater than placebo. Weight loss was still continuing in the highest three doses at the end of the study. When drugs were discontinued patients regained weight, as expected. Side effects were generally mild and were most evident in the group treated with the highest dose. These studies suggest that sibutramine may be a valuable new drug for treatment of obesity.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
JAMAIncreasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991
2,387 Citations1994Robert J. Kuczmarski
Observed trends in overweight prevalence and body mass index of the US adult population suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000.
JAMAIncreasing Prevalence of Overweight Among US Adults
1,570 Citations1994Robert J. Kuczmarski
Observations suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000.
The LancetINTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
310 Citations1989B Guy-Grand, Gaetano Crepaldi +4 more
In a randomised, placebo-controlled, double-blind study, 822 obese patients of both sexes were given either dexfenfluramine, 15 mg twice daily (404), or placebo in addition to a calorie-restricted diet for 1 year.
Annals of Internal MedicineUse and Abuse of Appetite-Suppressant Drugs in the Treatment of Obesity
183 Citations1993George A. Bray
This report addresses the use and abuse of appetite-suppressant drugs in the treatment of obesity with a focus on dinitrophenol, a drug that was noted to increase metabolism and to produce weight loss.
Annals of Internal MedicineMethods for Voluntary Weight Loss and Control
167 Citations1993NIH Technology Assessment Conference Panel
To evaluate methods for voluntary weight loss and control, the National Institutes of Health Nutrition Coordinating Committee and the Office of Medical Applications of Research held a technology assessment conference and agreed on answers to the following questions.
Medical Clinics of North AmericaDiagnosis and Prevalence of Obesity
151 Citations1989David S. Gray
Relative weight and BMI are used as indices of obesity, which may be defined as a BMI greater than 30 kg per m2, which corresponds to a relative weight approximately 120 per cent above desirable.
PubMedLipase inhibition: a novel concept in the treatment of obesity.
151 Citations1993Marjolein Drent, E. A. van der Veen
Orlistat (Ro 18-0647) is an inhibitor of gastric, carboxylester and pancreatic lipase and specifically reduces the absorption of dietary fat due to the inhibition of triglyceride hydrolysis and can be used for the treatment of obesity.
Progress in Neuro-Psychopharmacology and Biological PsychiatryThe pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation
149 Citations1988W. R. Buckett, P. C. Thomas +1 more
BTS 54 524 possesses a pharmacological profile which suggests that it may be a potent antidepressant with a rapid onset of action, and with a low potential for causing side-effects.
MetabolismThermogenic synergism between ephedrine and caffeine in healthy volunteers: A double-blind, placebo-controlled study
133 Citations1991Arne Astrup, Søren Toubro +3 more
The thermogenic effect after E + C 20 mg/200 mg was larger than that of any of the other combinations, and all combinations increased plasma glucose, insulin, and C-peptide from their ephedrine content.
Clinical Pharmacology & TherapeuticsSibutramine in weight control: A dose-ranging, efficacy study
122 Citations1991Michael Weintraub, Ana Rubio +3 more
Sibutramine, 5 and 20 mg, added to a multimodal program assisted participants in losing weight and showed a significant dose‐effect relationship.
American Journal of Clinical NutritionFluoxetine's effect on weight loss in obese subjects
116 Citations1991LL Darga, Leslie Carroll-Michals +2 more
By the end of the study, each group weighed significantly less than they did at baseline although the difference between groups was no longer significant (P greater than 0.05), and those on fluoxetine regained a mean of 4.2 kg from their lowest weight whereas the placebo group did not.
American Journal of Clinical NutritionLong-term weight loss: the effect of pharmacologic agents
98 Citations1994Goldstein Dj, JH Potvin
The benefits of extended treatment appear to outweigh the risks for those patients who are unable to lose sufficient weight without pharmacologic therapy but who maintain adequate weight loss with long-term pharmacologic Therapy.
MetabolismThe effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
81 Citations1992Arne Astrup, B Buemann +5 more
Findings provide evidence that promotion of fat loss and preservation of FFM during weight reduction may also be achieved pharmacologically in humans.
PubMedUse of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
74 Citations1989Louise R. Levine, Gregory G. Enas +8 more
Fluoxetine 60 mg daily appears to be potentially effective for use in weight reduction, and there were statistically significant dose-dependent increases in reports of asthenia, somnolence and sweating.
Annals of Internal MedicineBarriers to the Treatment of Obesity
52 Citations1991George A. Bray
There is clear and convincing evidence that modern appetite-suppressant drugs are effective and safe, however, there are several barriers to the proper use of these drugs and other treatments.
Obesity ResearchEvaluation of Drugs for Treating Obesity
47 Citations1995George A. Bray
The observation that patients regain weight after stopping drug treatment for obesity argues for the proposition that drugs work only when taken and NOT that the drugs are ineffective.
PsychopharmacologyEffect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl
45 Citations1990Graham P. Luscombe, Nigel A. Slater +4 more
The inhibition of monoamine uptake following sibutramine HCl administration to man is consistent with an antidepressant effect, and probably at least partly reflects inhibition of uptake by drug metabolites in both species.
Medical Clinics of North AmericaDrug Treatment of Obesity
42 Citations1989Michael Weintraub, George A. Bray
Use of drugs for the treatment of obesity is regarded more skeptically than drug use in other chronic disease; this view, however, may be inappropriate.